Serological responses to human virome define clinical outcomes of Italian patients infected with SARS-CoV-2

Wang, Limin; Candia, Julián; Ma, Lichun; Zhao, Yongmei; Imberti, Luisa; Sottini, Alessandra; Quiros-Roldan, Eugenia; Dobbs, Kerry; Burbelo, Peter D.; Cohen, Jeffrey I.; Delmonte, Ottavia M.; Forgues, Marshonna; Liu, Hui; Matthews, Helen F.; Shaw, Elana; Stack, Michael A.; Weber, Sarah E.; Zhang, Yu; Lisco, Andrea; Sereti, Irini; Su, Helen C.; Notarangelo, Luigi D.; Wang, Xin Wei

doi:10.7150/ijbs.78002



Theranostics

International Journal of Medical Sciences

Nanotheranostics

Journal of Cancer

Journal of Genomics

Global reach, higher impact

Full Text | PDF

Int J Biol Sci 2022; 18(15):5591-5606. doi:10.7150/ijbs.78002 This issue Cite

Research Paper

Serological responses to human virome define clinical outcomes of Italian patients infected with SARS-CoV-2

Limin Wang^1,12, Julián Candia^1,12, Lichun Ma^1,12, Yongmei Zhao^2,12, Luisa Imberti³, Alessandra Sottini³, Eugenia Quiros-Roldan⁴, Kerry Dobbs⁵, Peter D. Burbelo⁶, Jeffrey I. Cohen⁷, Ottavia M. Delmonte⁵, Marshonna Forgues¹, Hui Liu⁵, Helen F. Matthews⁸, Elana Shaw⁵, Michael A. Stack⁵, Sarah E. Weber⁹, Yu Zhang⁵, Andrea Lisco¹⁰, Irini Sereti¹⁰, Helen C. Su⁵, Luigi D. Notarangelo^5,✉, Xin Wei Wang^1,11,13,✉

1. Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892
2. CCR-SF Bioinformatics Group, Advanced Biomedical and Computational Sciences, Frederick National Laboratory for Cancer Research, 8560 Progress Drive, Frederick, Maryland 21701
3. CREA Laboratory, Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy
4. Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili, Brescia, Italy
5. Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892
6. National Institute of Dental and Craniofacial Research, NIH, Bethesda, Maryland 20892
7. Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892
8. Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892
9. Section of Molecular Development of the Immune System, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892
10. Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892
11. Liver Cancer Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892
12. These authors contributed equally
13. Lead Contact

Citation:

Wang L, Candia J, Ma L, Zhao Y, Imberti L, Sottini A, Quiros-Roldan E, Dobbs K, Burbelo PD, Cohen JI, Delmonte OM, Forgues M, Liu H, Matthews HF, Shaw E, Stack MA, Weber SE, Zhang Y, Lisco A, Sereti I, Su HC, Notarangelo LD, Wang XW. Serological responses to human virome define clinical outcomes of Italian patients infected with SARS-CoV-2. Int J Biol Sci 2022; 18(15):5591-5606. doi:10.7150/ijbs.78002. https://www.ijbs.com/v18p5591.htm

Other styles

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the pandemic respiratory infectious disease COVID-19. However, clinical manifestations and outcomes differ significantly among COVID-19 patients, ranging from asymptomatic to extremely severe, and it remains unclear what drives these disparities. Here, we studied 159 sequentially enrolled hospitalized patients with COVID-19-associated pneumonia from Brescia, Italy using the VirScan phage-display method to characterize circulating antibodies binding to 96,179 viral peptides encoded by 1,276 strains of human viruses. SARS-CoV-2 infection was associated with a marked increase in immune antibody repertoires against many known pathogenic and non-pathogenic human viruses. This antiviral antibody response was linked to longitudinal trajectories of disease severity and was further confirmed in additional 125 COVID-19 patients from the same geographical region in Northern Italy. By applying a machine-learning-based strategy, a viral exposure signature predictive of COVID-19-related disease severity linked to patient survival was developed and validated. These results provide a basis for understanding the role of memory B-cell repertoire to viral epitopes in COVID-19-related symptoms and suggest that a unique anti-viral antibody repertoire signature may be useful to define COVID-19 clinical severity.

Citation styles

APA

Wang, L., Candia, J., Ma, L., Zhao, Y., Imberti, L., Sottini, A., Quiros-Roldan, E., Dobbs, K., Burbelo, P.D., Cohen, J.I., Delmonte, O.M., Forgues, M., Liu, H., Matthews, H.F., Shaw, E., Stack, M.A., Weber, S.E., Zhang, Y., Lisco, A., Sereti, I., Su, H.C., Notarangelo, L.D., Wang, X.W. (2022). Serological responses to human virome define clinical outcomes of Italian patients infected with SARS-CoV-2. International Journal of Biological Sciences, 18(15), 5591-5606. https://doi.org/10.7150/ijbs.78002.

ACS

Wang, L.; Candia, J.; Ma, L.; Zhao, Y.; Imberti, L.; Sottini, A.; Quiros-Roldan, E.; Dobbs, K.; Burbelo, P.D.; Cohen, J.I.; Delmonte, O.M.; Forgues, M.; Liu, H.; Matthews, H.F.; Shaw, E.; Stack, M.A.; Weber, S.E.; Zhang, Y.; Lisco, A.; Sereti, I.; Su, H.C.; Notarangelo, L.D.; Wang, X.W. Serological responses to human virome define clinical outcomes of Italian patients infected with SARS-CoV-2. Int. J. Biol. Sci. 2022, 18 (15), 5591-5606. DOI: 10.7150/ijbs.78002.

NLM

CSE

Wang L, Candia J, Ma L, Zhao Y, Imberti L, Sottini A, Quiros-Roldan E, Dobbs K, Burbelo PD, Cohen JI, Delmonte OM, Forgues M, Liu H, Matthews HF, Shaw E, Stack MA, Weber SE, Zhang Y, Lisco A, Sereti I, Su HC, Notarangelo LD, Wang XW. 2022. Serological responses to human virome define clinical outcomes of Italian patients infected with SARS-CoV-2. Int J Biol Sci. 18(15):5591-5606.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.